Vienna, Austria

ESTRO 2023

Session Item

Saturday
May 13
10:30 - 11:30
Business Suite 1-2
Lung 1
Jose Belderbos, The Netherlands
1300
Poster Discussion
Clinical
Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer
Jörg Andreas Müller, Germany
PD-0156

Abstract

Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer
Authors:

Jörg Andreas Müller1

1University hospital Halle (Saale), Radiation Oncology, Halle (Saale), Germany

Show Affiliations
Purpose or Objective

Stereotactic body radiotherapy (SBRT) is an established treatment method with favourable toxicity for inopera-ble early stage non-small-cell lung cancer (NSCLC) patients. This paper aims to evaluate the importance of SBRT in the treatment of early-stage lung cancer patients compared to surgery as standard of care.



Material and Methods

The German clinical cancer registry of Berlin-Brandenburg was assessed. Cases of lung cancer were considered, if they had a TNM stage (clinical or pathological) of T1-T2a and N0/x and M0/x corresponding to the UICC stages I and II. In our analyses, cases diagnosed between 2000 and 2015 were included. We adjusted our models with propensity score matching. We compared patients treated with SBRT or surgery regarding age, Karnofsky performance status (KPS), sex, histological grade and TNM-classification. Further, we assessed the association of cancer-related parameters with mortality, hazard ratios (HR) from Cox proportional hazards models were computed.

Results

A total of 558 patients with UICC stages I and II NSCLC were analyzed. In univariate survival models, we found similar survival rates in patients who underwent radiotherapy compared with surgery (HR: 1.2, 95% CI 0.92-1.56, p=0,2). Our univariate subgroup analyses of patients >75 years showed a statistically non-significant survival benefit for patients treated with SBRT (HR: 0.86, 95% CI 0.54-1.35, p=0,5). Likewise, in our T1 sub-analysis survival rates were similar between the two treatment groups regarding overall survival (HR: 1.12, 95% CI 0.57-2.19, p=0,7). The availability of histological data might be slightly beneficial in terms of survival (HR: 0.89, 95% CI 0.68-1.15, p=0,4). This effect was also not significant. Regarding the availability of histological status in our subgroup analyses of elderly patients, we could show similar survival rates as well (HR: 0.70, 95% CI 0.44-1.23, p=0,14). T1-staged patients had also a statistically non-significant survival benefit if histological grading was available (HR: 0.75, 95% CI 0.39-1.44, p=0,4). Concerning adjusted covariates, better KPS scores were associated with a better survival in our matched univariate cox regression models. Further, higher histolog-ical grades and TNM-stages were related to a higher mortality risk.

Conclusion

Using population-based data, we observed an almost equal survival of patients treated with SBRT compared to surgery in stage I and II lung cancer. The availability of histological status might not be decisive in therapy planning. SBRT is comparable to surgery in terms of survival.